Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 |
Tel: | N/A |
Website: | https://www.bioventus.com |
IR: | See website |
Key People | ||
Anthony P. Bihl Interim Chief Executive Officer, Director | Mark Singleton Chief Financial Officer, Senior Vice President | Katrina Church Senior Vice President, Chief Compliance Officer |
Anthony D'adamio Senior Vice President, General Counsel | Sharon W. Klugewicz Senior Vice President - Quality and Regulatory Affairs |
Business Overview |
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions consist of bone graft substitutes (BGS) to fuse and grow bones and ultrasonic medical devices used for precise bone sculpting, removal of tumors, and tissue debridement in various surgeries, including spine and neurosurgery. Its Restorative Therapies consist of an ultrasonic bone healing system for fracture care, and advanced rehabilitation devices designed to help patients regain leg or hand function due to stroke. |
Financial Overview |
For the nine months ended 30 September 2023, Bioventus Inc revenues decreased 2% to $376.9M. Net loss before extraordinary items increased less than 1% to $90.6M. Revenues reflect U.S. segment decrease of 5% to $331.1M. Net income reflects Impairment of assets decrease of 37% to $78.6M (expense), Selling, general ane expe decrease of 10% to $219.3M (expense). |
Employees: | 970 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $696.19M as of Sep 30, 2023 |
Annual revenue (TTM): | $502.76M as of Sep 30, 2023 |
EBITDA (TTM): | $90.95M as of Sep 30, 2023 |
Net annual income (TTM): | -$122.57M as of Sep 30, 2023 |
Free cash flow (TTM): | -$0.18M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $367.79M as of Sep 30, 2023 |
Shares outstanding: | 78,752,567 as of Oct 27, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |